CA-ZYNGA
5.3.2020 12:02:06 CET | Business Wire | Press release
Today, Zynga Inc. (Nasdaq:ZNGA), a global leader in interactive entertainment, announced the soft launch of Harry Potter: Puzzles & Spells in select markets. Officially licensed from Warner Bros. Interactive Entertainment and published under the Portkey Games label, the game weaves innovative match-3 puzzle gameplay with the iconic characters, narrative, settings, spell-casting and magical mischief of the Wizarding World.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200305005226/en/
“We are incredibly proud to bring Harry Potter to Zynga's portfolio and are dedicated to creating a game that's worthy of the Wizarding World and its legions of fans,” said Bernard Kim, President of Publishing at Zynga. “By combining the ubiquity of mobile and the expertise of Zynga’s development team in partnership with Warner Bros. Interactive Entertainment, we are crafting a game that will delight fans of all ages around the globe.”
Fans have continued to honour and extend the wonder of the Wizarding World by engaging in Harry Potter quizzes, brain teasers and other puzzle-inspired play. Harry Potter: Puzzles & Spells celebrates this affinity for challenge and mystery with the first match-3 puzzle game for mobile devices. In the game, players create their own persona and experience the excitement and mysteries of the Wizarding World in an enchanting new way. Unlocking Wizarding World elements, including new spells and brewing potions as they progress, players will encounter the most iconic moments and memorable faces from the original Harry Potter films. Utilising magic abilities and objects to prevail, players will face matching puzzles populated with Chocolate Frogs and other obstacles as they “swish and flick” through fanciful levels.
Proving their magical mettle, players will earn experience points as they progress in the game. From Daily Events to interactive puzzles, players will earn XP to gain new magical abilities and rewards, level up their skills and spells, as well as customise their unique, in-game personas. Players will also have the option to form clubs and join forces with other fans to socialise, participate in special in-game cooperative activities and experience the camaraderie of the Wizarding World.
Fans can visit www.zynga.com to stay tuned for further updates for Harry Potter: Puzzles & Spells , which will launch worldwide for iOS and Android devices, as well as Amazon Kindle and Facebook.
About Zynga
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises, including: CSR Racing™
, Empires & Puzzles™, Merge Dragons! ™
, Words With Friends™
and Zynga Poker™.
Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with studios in the US, Canada, UK, Ireland, India, Turkey and Finland. For more information, visit www.zynga.com
or follow Zynga on Twitter
, Instagram
, Facebook
or the Zynga blog
.
About Warner Bros. Interactive Entertainment
Warner Bros. Interactive Entertainment, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles.
About Portkey Games
Portkey Games, from Warner Bros. Interactive Entertainment, is the games label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. Portkey Games offers players the opportunity to make their own narrative choices and engage with the Wizarding World setting to create new and unique experiences. The label was created to bring gamers and fans new gaming experiences that allow them to delve into the magic of the Wizarding World in immersive ways where they can define their own Wizarding World story.
Forward Looking Statements
This press release contains forward-looking statements relating to, among other things, the name, release timeframe, and gameplay details of an upcoming Harry Potter game. Forward-looking statements often include words such as “outlook,” “projected,” “planned,” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com
or the SEC’s website at www.sec.gov
.
WIZARDING WORLD, HARRY POTTER Publishing Rights © J.K. Rowling. HARRY POTTER: PUZZLES & SPELLS, PORTKEY GAMES, WIZARDING WORLD and HARRY POTTER characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. ™ Zynga Inc. All Rights Reserved.
WBIE LOGO, WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s20)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom